194 related articles for article (PubMed ID: 26593700)
1. The Molecular Basis for Dual Fatty Acid Amide Hydrolase (FAAH)/Cyclooxygenase (COX) Inhibition.
Palermo G; Favia AD; Convertino M; De Vivo M
ChemMedChem; 2016 Jun; 11(12):1252-8. PubMed ID: 26593700
[TBL] [Abstract][Full Text] [Related]
2. Dual cyclooxygenase-fatty acid amide hydrolase inhibitor exploits novel binding interactions in the cyclooxygenase active site.
Goodman MC; Xu S; Rouzer CA; Banerjee S; Ghebreselasie K; Migliore M; Piomelli D; Marnett LJ
J Biol Chem; 2018 Mar; 293(9):3028-3038. PubMed ID: 29326169
[TBL] [Abstract][Full Text] [Related]
3. Multitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal anti-inflammatory drug-dependent gastrointestinal damage.
Sasso O; Migliore M; Habrant D; Armirotti A; Albani C; Summa M; Moreno-Sanz G; Scarpelli R; Piomelli D
FASEB J; 2015 Jun; 29(6):2616-27. PubMed ID: 25757568
[TBL] [Abstract][Full Text] [Related]
4. Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.
Migliore M; Habrant D; Sasso O; Albani C; Bertozzi SM; Armirotti A; Piomelli D; Scarpelli R
Eur J Med Chem; 2016 Feb; 109():216-37. PubMed ID: 26774927
[TBL] [Abstract][Full Text] [Related]
5. A Double Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation.
Scarpelli R; Sasso O; Piomelli D
ChemMedChem; 2016 Jun; 11(12):1242-51. PubMed ID: 26486424
[TBL] [Abstract][Full Text] [Related]
6. Exploring the fatty acid amide hydrolase and cyclooxygenase inhibitory properties of novel amide derivatives of ibuprofen.
Deplano A; Karlsson J; Svensson M; Moraca F; Catalanotti B; Fowler CJ; Onnis V
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):815-823. PubMed ID: 32200655
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of fatty acid amide hydrolase and cyclooxygenase by the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen.
Cipriano M; Björklund E; Wilson AA; Congiu C; Onnis V; Fowler CJ
Eur J Pharmacol; 2013 Nov; 720(1-3):383-90. PubMed ID: 24120370
[TBL] [Abstract][Full Text] [Related]
8. Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs.
Reddy RN; Mutyala R; Aparoy P; Reddanna P; Reddy MR
Curr Pharm Des; 2007; 13(34):3505-17. PubMed ID: 18220787
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor.
Favia AD; Habrant D; Scarpelli R; Migliore M; Albani C; Bertozzi SM; Dionisi M; Tarozzo G; Piomelli D; Cavalli A; De Vivo M
J Med Chem; 2012 Oct; 55(20):8807-26. PubMed ID: 23043222
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition.
Limongelli V; Bonomi M; Marinelli L; Gervasio FL; Cavalli A; Novellino E; Parrinello M
Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5411-6. PubMed ID: 20215464
[TBL] [Abstract][Full Text] [Related]
11. Interaction of the N-(3-Methylpyridin-2-yl)amide Derivatives of Flurbiprofen and Ibuprofen with FAAH: Enantiomeric Selectivity and Binding Mode.
Karlsson J; Morgillo CM; Deplano A; Smaldone G; Pedone E; Luque FJ; Svensson M; Novellino E; Congiu C; Onnis V; Catalanotti B; Fowler CJ
PLoS One; 2015; 10(11):e0142711. PubMed ID: 26565710
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor.
Gouveia-Figueira S; Karlsson J; Deplano A; Hashemian S; Svensson M; Fredriksson Sundbom M; Congiu C; Onnis V; Fowler CJ
PLoS One; 2015; 10(9):e0139212. PubMed ID: 26406890
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and
Deplano A; Karlsson J; Moraca F; Svensson M; Cristiano C; Morgillo CM; Fowler CJ; Russo R; Catalanotti B; Onnis V
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):940-953. PubMed ID: 33896320
[TBL] [Abstract][Full Text] [Related]
14. Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding Network.
Xu S; Hermanson DJ; Banerjee S; Ghebreselasie K; Clayton GM; Garavito RM; Marnett LJ
J Biol Chem; 2014 Mar; 289(10):6799-6808. PubMed ID: 24425867
[TBL] [Abstract][Full Text] [Related]
15. A binding site for nonsteroidal anti-inflammatory drugs in fatty acid amide hydrolase.
Bertolacci L; Romeo E; Veronesi M; Magotti P; Albani C; Dionisi M; Lambruschini C; Scarpelli R; Cavalli A; De Vivo M; Piomelli D; Garau G
J Am Chem Soc; 2013 Jan; 135(1):22-5. PubMed ID: 23240907
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic insights into cyclooxygenase irreversible inactivation by aspirin.
Tosco P; Lazzarato L
ChemMedChem; 2009 Jun; 4(6):939-45. PubMed ID: 19301318
[TBL] [Abstract][Full Text] [Related]
17. Benzimidazole scaffold based hybrid molecules for various inflammatory targets: Synthesis and evaluation.
Kaur G; Silakari O
Bioorg Chem; 2018 Oct; 80():24-35. PubMed ID: 29864685
[TBL] [Abstract][Full Text] [Related]
18. The fatty acid amide hydrolase and cyclooxygenase-inhibitory properties of novel amide derivatives of carprofen.
Deplano A; Karlsson J; Fowler CJ; Onnis V
Bioorg Chem; 2020 Aug; 101():104034. PubMed ID: 32599361
[TBL] [Abstract][Full Text] [Related]
19. Ruthenium(ii) arene NSAID complexes: inhibition of cyclooxygenase and antiproliferative activity against cancer cell lines.
Mandal P; Kundu BK; Vyas K; Sabu V; Helen A; Dhankhar SS; Nagaraja CM; Bhattacherjee D; Bhabak KP; Mukhopadhyay S
Dalton Trans; 2018 Jan; 47(2):517-527. PubMed ID: 29235601
[TBL] [Abstract][Full Text] [Related]
20. Isoxazole-Based-Scaffold Inhibitors Targeting Cyclooxygenases (COXs).
Perrone MG; Vitale P; Panella A; Ferorelli S; Contino M; Lavecchia A; Scilimati A
ChemMedChem; 2016 Jun; 11(11):1172-87. PubMed ID: 27136372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
